SCHEMBL25168554

SCHEMBL25168554

CC(c1ccc(C(=O)O)cc1)N1CCN(c2ccncn2)CC1

nearest known ligand 0.58

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
OGA O60502 14/20 0.58
SORD Q00796 1/20 0.42
AKT1 P31749 1/20 0.41
GPR119 Q8TDV5 1/20 0.41
PARP1 P09874 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25168553 1.00 OGA (0.58) OGASORDAKT1GPR119PARP1
SCHEMBL26199251 0.87 OGA (0.60) OGAGPR119PARP1
SCHEMBL30368658 0.87 OGA (0.60) OGAGPR119PARP1
SCHEMBL28688720 0.87 OGA (0.60) OGAGPR119PARP1
SCHEMBL25171545 0.81 SORD (0.52) OGASORDAKT1
SCHEMBL30179830 0.81 SORD (0.52) OGASORDAKT1
SCHEMBL25171542 0.81 SORD (0.52) OGASORDAKT1
SCHEMBL30179821 0.79 OGA (0.45) OGASORDAKT1
SCHEMBL25168524 0.79 OGA (0.45) OGASORDAKT1
SCHEMBL25168525 0.79 OGA (0.45) OGASORDAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271933-A1 HETEROCYCLIC IMMUNOMODULATOR BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) 2023-08-31 US disclosed
EP-4177247-A1 HETEROCYCLIC IMMUNOMODULATOR Beijing InnoCare Pharma Tech Co., Ltd. (CN) 2023-05-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271933-A1 HETEROCYCLIC IMMUNOMODULATOR IL2, ICOS, IL5 OGA 3260/4885SORD 1657/4885AKT1 3977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.